In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor ...

PDS Biotechnology (PDSB) announced the publication of clinical results in the Journal of the American Medical Association, JAMA, Oncology. The ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical ...

Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...